Daré Bioscience Launches Regulation A Preferred Unit Offering

The latest announcement is out from Daré Bioscience ( (DARE) ).

On January 23, 2026, Daré Bioscience filed a Certificate of Designation in Delaware creating a new Series A Convertible Preferred Stock, setting its liquidation preference at $5.00 per share, ranking it senior to common stock, eliminating dividend rights, and granting investors conversion features at an initial price of $2.50 per common share, subject to company call and forced-conversion provisions triggered by change of control, stock price performance, or a qualifying public offering, all structured to comply with Nasdaq rules on control and large issuances. On January 27, 2026, the company completed the initial closing of a Regulation A offering of up to 4,854,000 Investor Units—each comprising one Series A Preferred share and two common stock warrants at a $5.00 unit price—issuing 5,090 units plus related agent warrants in a best-efforts transaction led by Digital Offering, a move that initiates a rolling-capital raise without exchange listing for the new securities and potentially provides incremental funding capacity while limiting immediate dilution and change-of-control risks under Nasdaq thresholds.

The most recent analyst rating on (DARE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Spark’s Take on DARE Stock

According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.

The score is held down primarily by weak financial performance (minimal and declining revenue, ongoing losses, and TTM cash burn). Offsetting factors include a more positive recent strategic outlook from the earnings call (planned product launches and cash position) and a positive corporate event increasing control over Ovaprene, while technicals and valuation provide only limited near-term support.

To see Spark’s full report on DARE stock, click here.

More about Daré Bioscience

Daré Bioscience, Inc. is a Delaware-incorporated biopharmaceutical company whose capital structure includes common stock listed on Nasdaq and newly designated preferred stock, reflecting a financing strategy focused on equity-linked securities rather than dividends, with sensitivity to Nasdaq change-of-control and large-issuance rules.

Average Trading Volume: 160,881

Technical Sentiment Signal: Strong Sell

Current Market Cap: $28.15M

For an in-depth examination of DARE stock, go to TipRanks’ Overview page.